<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 2)*
Under the Securities Exchange Act of 1934
BIOGEN,INC.
-----------
(Name of Issuer)
COMMON STOCK
------------
(Title of Class of Securities)
090597105
---------
(CUSIP Number)
Daniel Schlatter Copy to: Daniel L. Goelzer, Esq.
Theaterstrasse 12, Baker & McKenzie
8024 Zurich, CH/Switzerland 815 Connecticut Ave., N.W.
41-1-267-67-67 Washington, D.C. 20006
-----------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
February 23, 1996
-----------------
(Date of Event which Requires
Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the following
box / /.
Check the following box if a fee is being paid with the statement / /.
(A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent of
the class of securities described in Item 1; and (2) has filed no amendment
subsequent thereto reporting beneficial ownership of five percent or less of
such class.) (See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be
filed with the Commission. See Rule 13d-1(a) for other parties to whom copies
are to be sent.
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities and for any subsequent amendment containing information which would
alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
Page 1 of 7 Pages
<PAGE> 2
CUSIP No. 090597105
- --------------------------------------------------------------------------------
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
BB Biotech AG
- --------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /x/
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source of Funds (See Instructions)
WC
- --------------------------------------------------------------------------------
(5) Check Box if Disclosure of Legal Proceedings / /
is Required Pursuant to Item 2(d) or 2(e)
- --------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
Switzerland
- --------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power:
Beneficially Owned 0
by Each Reporting ------------------------------
Person With (8) Shared Voting Power
411,100
------------------------------
(9) Sole Dispositive Power
0
------------------------------
(10) Shared Dispositive Power
411,100
------------------------------
- --------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
411,100 shares
- --------------------------------------------------------------------------------
(12) Check Box if the Aggregate Amount in Row (11) / /
Excludes Certain Shares (See Instructions)
- --------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
1.12%
- --------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions)
HC, CO
- --------------------------------------------------------------------------------
Page 2 of 7 Pages
<PAGE> 3
CUSIP No. 090597105
- --------------------------------------------------------------------------------
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Biotech Invest S.A.
- --------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /x/
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source of Funds (See Instructions)
WC
- --------------------------------------------------------------------------------
(5) Check Box if Disclosure of Legal Proceedings / /
is Required Pursuant to Item 2(d) or 2(e)
- --------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
Panama
- --------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 0
by Each Reporting -----------------------------
Person With (8) Shared Voting Power
0
-----------------------------
(9) Sole Dispositive Power
0
-----------------------------
(10) Shared Dispositive Power
0
-----------------------------
- --------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
None
- --------------------------------------------------------------------------------
(12) Check Box if the Aggregate Amount in Row (11) / /
Excludes Certain Shares (See Instructions)
- --------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
None
- --------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions)
CO
- --------------------------------------------------------------------------------
Page 3 of 7 Pages
<PAGE> 4
CUSIP No. 090597105
- --------------------------------------------------------------------------------
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Biotech Focus S.A.
- --------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /x/
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source of Funds (See Instructions)
WC
- --------------------------------------------------------------------------------
(5) Check Box if Disclosure of Legal Proceedings / /
is Required Pursuant to Item 2(d) or 2(e)
- --------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
Panama
- --------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 411,100
by Each Reporting -----------------------------
Person With (8) Shared Voting Power
0
-----------------------------
(9) Sole Dispositive Power
411,100
-----------------------------
(10) Shared Dispositive Power
0
-----------------------------
- --------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
411,100 shares
- --------------------------------------------------------------------------------
(12) Check Box if the Aggregate Amount in Row (11) / /
Excludes Certain Shares (See Instructions)
- --------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
1.12%
- --------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions)
CO
- --------------------------------------------------------------------------------
Page 4 of 7 Pages
<PAGE> 5
CUSIP No. 090597105
- --------------------------------------------------------------------------------
(1) Name of Reporting Person
S.S. or I.R.S. Identification No. of Above Person
Biotech Target S.A.
- --------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /x/
- --------------------------------------------------------------------------------
(3) SEC Use Only
- --------------------------------------------------------------------------------
(4) Source of Funds (See Instructions)
WC
- --------------------------------------------------------------------------------
(5) Check Box if Disclosure of Legal Proceedings / /
is Required Pursuant to Item 2(d) or 2(e)
- --------------------------------------------------------------------------------
(6) Citizenship or Place of Organization
Panama
- --------------------------------------------------------------------------------
Number of Shares (7) Sole Voting Power
Beneficially Owned 0
by Each Reporting -----------------------------
Person With (8) Shared Voting Power
0
-----------------------------
(9) Sole Dispositive Power
0
-----------------------------
(10) Shared Dispositive Power
0
-----------------------------
- --------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person
None
- --------------------------------------------------------------------------------
(12) Check Box if the Aggregate Amount in Row (11) / /
Excludes Certain Shares (See Instructions)
- --------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11)
None
- --------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions)
CO
- --------------------------------------------------------------------------------
Page 5 of 7 Pages
<PAGE> 6
SCHEDULE 13D
This Amendment No. 2 reflects open market sales of 2,428,900 shares of
common stock, par value $.01 per share ("Common Stock"), of Biogen, Inc.
("Biogen") by (i) BB Biotech AG, a Swiss corporation ("BB Biotech"), (ii)
Biotech Invest S.A., a Panamanian corporation ("Biotech Invest"), (iii) Biotech
Focus, S.A., a Panamanian corporation ("Biotech Focus") and (iv) Biotech Target
S.A., a Panamanian corporation ("Biotech Target", Biotech Invest, Biotech Focus
and Biotech Target are collectively referred to as the "Biotech Subsidiaries").
As of February 23, 1996, BB Biotech and the Biotech Subsidiaries ceased to have
beneficial ownership of more than 5 percent of the Common Stock of Biogen.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
ITEMS 5(a), (b), (c) AND (e) ARE AMENDED IN THEIR ENTIRETY TO READ AS
FOLLOWS:
(a) The Biotech Subsidiaries collectively held 2,840,000 shares,
or approximately 8.25 percent, of Biogen Common Stock on July 6, 1994 (the
filing date of Amendment No. 1 to Schedule 13D). As of February 23, 1996, the
Biotech Subsidiaries held 1,693,400 shares, or approximately 4.61 percent, of
Biogen Common Stock. Since that time, the Biogen Subsidiaries have sold shares
in the open market to reduce their holdings to 411,100 shares, or approximately
1.12 percent of the outstanding Common Stock of Biogen as of March 7, 1996. As
a result, BB Biotech may be deemed to be the indirect beneficial owner of the
411,100 shares of Biogen Common Stock held directly in the aggregate by the
Biotech Focus as of March 7, 1996, which represents approximately 1.12 percent
of the outstanding shares of Biogen Common Stock. No shares of Biogen Common
Stock are directly owned by BB Biotech. To the best knowledge of BB Biotech
and the Biotech Subsidiaries, no director or executive officer of BB Biotech or
the Biotech Subsidiaries owns any shares of Biogen Common Stock.
(b) The number of shares of Biogen Common Stock to which there is
sole power to vote or to direct the vote, shares power to vote or to direct the
vote, sole power to dispose or to direct the disposition, or shared power to
dispose or direct the disposition is set forth in the cover pages and such
information is incorporated herein by reference. BB Biotech, through its
ownership of the Biotech Subsidiaries, may be deemed to beneficially own the
shares of Biogen Common Stock within the meaning of Regulation 13D under the
Exchange Act, and may be deemed to share with the Biotech Subsidiaries the
power to vote or direct the vote of and the power to dispose of or direct the
disposition of the aggregate 411,100 shares of Biogen Common Stock held by
Biotech Focus. BB Biotech hereby expressly declares that the filing of this
statement shall not be construed as an admission that it is, for purposes of
Section 13(d) of the Exchange Act, the beneficial owner of the shares of Biogen
Common Stock held by the Biotech Subsidiaries.
(c) A summary of transactions in Biogen Common Stock effected by
the Biotech Subsidiaries during the past sixty days is attached hereto as
Exhibit A and such information is incorporated herein by reference.
(e) As of February 23, 1996, BB Biotech and the Biotech
Subsidiaries ceased to have beneficial ownership of more than 5 percent of the
Common Stock of Biogen.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
ITEM 7 IS HEREBY AMENDED TO ADD THE FOLLOWING:
Exhibit H: Agreement by and among BB Biotech, Biotech Invest, Biotech
Focus, and Biotech Target with respect to the filing of this
Amendment No. 2 to a statement on Schedule 13D dated March 13,
1996.
Page 6 of 7 Pages
<PAGE> 7
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
BB BIOTECH AG
Date: March 13, 1996 By:/s/ Daniel Schlatter
----------------------------------------
Name: Daniel Schlatter
Title: Counsel
By:/s/ Dr. Ernst Mueller-Moehl
----------------------------------------
Name: Dr. Ernst Mueller-Moehl
BIOTECH INVEST, S.A.
Date: March 13, 1996 By:/s/ Daniel Schlatter
----------------------------------------
Name: Daniel Schlatter
Title: Counsel
BIOTECH FOCUS, S.A.
Date: March 13, 1996 By:/s/ Daniel Schlatter
----------------------------------------
Name: Daniel Schlatter
Title: Counsel
BIOTECH TARGET, S.A.
Date: March 13, 1996 By:/s/ Daniel Schlatter
----------------------------------------
Name: Daniel Schlatter
Title: Counsel
Page 7 of 7 Pages
<PAGE> 8
EXHIBIT INDEX
-------------
EXHIBIT 99.A - AMENDED TRANSACTION SUMMARY.
EXHIBIT 99.H - JOINT FILING AGREEMENT.
<PAGE> 1
Exhibit A
EXHIBIT A IS HEREBY AMENDED TO ADD THE FOLLOWING SUMMARY OF
TRANSACTIONS IN BIOGEN COMMON STOCK EFFECTED BY THE BIOTECH SUBSIDIARIES FROM
JANUARY 17, 1996 THROUGH MARCH 7, 1996.
<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------------------
DATE TYPE OF TRANSACTION, NUMBER, BENEFICIALLY TOTAL SHARES PERCENT
CLASS AND PRICE OF SHARES OWNED OUTSTANDING OF OUTSTANDING
SHARES OWNED
-------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
January 17, Sale of 10,000 shares of Common Stock. 2,100,000 36,720,000 5.72%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
January 22, Sale of 30,000 shares of Common Stock. 2,070,000 36,720,000 5.64%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
January 29, Sale of 50,000 shares of Common Stock. 2,020,000 36,720,000 5.50%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
January 30, Sale of 12,000 shares of Common Stock. 2,008,000 36,720,000 5.47%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
January 31, Sale of 8,000 shares of Common Stock. 2,000,000 36,720,000 5.45%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
February 12, Sale of 80,000 shares of Common Stock. 1,920,000 36,720,000 5.23%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
February 20, Sale of 50,000 shares of Common Stock. 1,870,000 36,720,000 5.09%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
February 21, Sale of 26,000 shares of Common Stock; purchase 1,901,000 36,720,000 5.18%
1996 of 57,000 shares of Common Stock. shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
February 23, Sale of 207,600 shares of Common Stock. 1,693,400 36,720,000 4.61%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 2
<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------------------
DATE TYPE OF TRANSACTION, NUMBER, BENEFICIALLY TOTAL SHARES PERCENT
CLASS AND PRICE OF SHARES OWNED OUTSTANDING OF OUTSTANDING
SHARES OWNED
-------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
February 26, Sale of 90,000 shares of Common Stock. 1,603,400 36,720,000 4.37%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
February 27, Sale of 167,300 shares of Common Stock. 1,436,100 36,720,000 3.91%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
February 28, Sale of 67,500 shares of Common Stock. 1,368,600 36,720,000 3.73%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
February 29, Sale of 93,000 shares of Common Stock. 1,274,800 36,720,000 3.47%
1996 shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
March 1, 1996 Sale of 61,000 shares of Common Stock. 1,213,800 36,720,000 3.31%
shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
March 4, 1996 Sale of 64,200 shares of Common Stock. 1,149,600 36,720,000 3.13%
shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
March 5, 1996 Sale of 12,200 shares of Common Stock; purchase 1,087,900 36,720,000 2.96%
of 67,700 shares of Common Stock. shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
March 6, 1996 Sale of 86,800 shares of Common Stock. 1,001,100 36,720,000 2.73%
shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
March 7, 1996 Sale of 590,000 shares of Common Stock. 411,100 36,720,000 1.12%
shares of Common
Stock
-------------------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE> 1
Exhibit H
JOINT FILING AGREEMENT
We, the undersigned, hereby express our agreement that the attached
Amendment No. 2 to a statement on Schedule 13D for the event dated February
23, 1996, is filed on behalf of each of the undersigned.
Date: March 13, 1996
BB BIOTECH AG
By: /s/ Daniel Schlatter
------------------------------------
Name: Daniel Schlatter
Title: Counsel
By: /s/ Dr. Ernst Mueller-Moehl
------------------------------------
Name: Dr. Ernst Mueller-Moehl
BIOTECH INVEST, S.A.
By: /s/ Daniel Schlatter
------------------------------------
Name: Daniel Schlatter
Title: Counsel
BIOTECH FOCUS, S.A.
By: /s/ Daniel Schlatter
------------------------------------
Name: Daniel Schlatter
Title: Counsel
BIOTECH TARGET, S.A.
By: /s/ Daniel Schlatter
------------------------------------
Name: Daniel Schlatter
Title: Counsel
